Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183

A radioimmunoconjugate consisting of the murine IgG1 monoclonal antibody BW250/183 labeled with yttrium Y 90 with potential radioimmunotherapeutic activity. Yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183 binds to a 95 kD nonspecific cross-reacting antigen (CD66b or NCA-95) on granulocytes, selectively delivering a cytotoxic dose of Y 90 beta radiation to CD66b-expressing cells. CD66b, a member of the carcinoembryonic antigen (CEA) family with an unknown function, appears early in the differentiation of granulopoietic cells and is expressed on the cell surface of almost all human granulocytes and their more mature precursors.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183

Search NCI's Drug Dictionary